| Mr. Zhou Gaobo, the   Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in   charge of the company's innovative drug investment and business development,   establishment of new investment platforms, as well as the investment strategy   planning and practice. Before joining   Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader   of the Greater China Healthcare practice. He has fifteen years of experience   in management consulting in the healthcare industry. He worked with leading   pharmaceutical, biotechnology, medical device, and life science investment   companies on a broad range of topics in China Healthcare Reform and   innovation, including strategy, business model innovation, digital   transformation, and investment and partnership. He also built the largest   healthcare management consulting team in the industry. Previously, he also   worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug   development. Mr. Gaobo Zhou holds   an MBA from Duke University, a Master's Degree in Biochemistry from the   University of Maryland and a Bachelor’s Degree in Genetics from Fudan   University. |